Evidence map›Paper›PMID 34930459›Full record

Trial reportInfectious diseases of poverty2021

Bioefficacy and durability of Olyset

Paul M Gichuki, Luna Kamau, Kiambo Njagi, Solomon Karoki, Njoroge Muigai, Damaris Matoke-Muhia, Nabie Bayoh, Evan Mathenge, Rajpal S Yadav

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Infectious diseases of poverty, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Behavioural responses ofCurrent research in parasitology & vector-borne diseases · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Paul M GichukiEastern & Southern Africa Centre of International Parasite Control, Kenya Medical Research Institute, Nairobi, Kenya. paulmgichuki@gmail.com.ORCID http://orcid.org/0000-0001-6558-5538
Luna KamauCentre for Biotechnology Research and Development, Kenya Medical Research Institute, Nairobi, Kenya.
Kiambo NjagiDivision of National Malaria Programme, Ministry of Health, Nairobi, Kenya.
Solomon KarokiDivision of National Malaria Programme, Ministry of Health, Nairobi, Kenya.
Njoroge MuigaiDepartment of Health, Kirinyaga County, Kirinyaga, Kenya.
Damaris Matoke-MuhiaCentre for Biotechnology Research and Development, Kenya Medical Research Institute, Nairobi, Kenya.
Nabie BayohCentre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Evan MathengeEastern & Southern Africa Centre of International Parasite Control, Kenya Medical Research Institute, Nairobi, Kenya.
Rajpal S YadavDepartment of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.ORCID http://orcid.org/0000-0001-8264-1204
Kenya Medical Research Institute · KEMinistry of Health · KEKirinyaga University · KEWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundLong-lasting insecticide nets (LLINs) are a core malaria intervention. LLINs should retain efficacy against mosquito vectors for a minimum of three years. Efficacy and durability of Olyset

methodsThis was a household randomized controlled trial in a malaria endemic rice cultivation zone of Kirinyaga County, Kenya between 2014 and 2017. Cone bioassays and tunnel tests were done against Anopheles gambiae Kisumu. The chemical content, fabric integrity and LLIN survivorship were monitored. Comparisons between nets were tested for significance using the Chi-square test. Exact binomial distribution with 95% confidence intervals (95% CI) was used for percentages. The WHO efficacy criteria used were ≥ 95% knockdown and/or ≥ 80% mortality rate in cone bioassays and ≥ 80% mortality and/or ≥ 90% blood-feeding inhibition in tunnel tests.

resultsAt 36 months, Olyset

conclusionsOlyset

Indexed as

InsecticidesPermethrinHumansKenyaPiperonyl ButoxideInsecticidesPermethrinPiperonyl ButoxideAnopheles gambiaeBioefficacyDurabilityKenyaLong-lasting insecticidal netOlyset® NetOlyset® PlusPermethrinPiperonyl butoxide

Identifiers

PMID34930459
PMCPMC8691082
OpenAlexW4200361426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.